Orphan drugs are still growing. But the environment they operate in is changing fast.
Rare disease therapies are forecast to generate over $400bn in global sales and represent more than 21% of prescription pharma sales by 2032. That scale has moved orphan drugs from the margins of portfolios to the center of strategic decision making.
In 2026, orphan drug developers face a more complex backdrop. Regulatory signals from the FDA are less consistent. The practical impact of the Inflation Reduction Act is still unfolding. Competition for capital is intensifying as obesity and other mass market therapies absorb attention.
Download the report to discover:
- Where orphan drug growth remains resilient, and where pressure is building
- The top orphan drugs and franchises in 2032, including Darzalex, Alyftrek, Winrevair, Vyvgart and Amvuttra
- Which companies are gaining momentum, and which are starting to lose ground
- The most valuable late stage orphan pipeline assets, ranked by net present value (NPV)
- What recent US policy shifts mean in practice for orphan drug pricing, exclusivity and development strategy
Access the report for a clear, data driven view of where value is building, where risk is rising, and what that means for rare disease portfolios.
